Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
Condition(s) studied
Investigational drug(s) / intervention(s)
No intervention: No intervention
Study summary
PURPOSE: To investigate the effect of the disease and HSCT on muscle dysfunction and to investigate the prognostic role of muscle dysfunction at critical decision points in patients with hematological diseases referred to hematopoietic stem cell transplant (HSCT).
HSCT: Patients diagnosed with malignant hematological diseases who are referred to myeloablative HSCT, to a myeloablative "reduced toxicity conditioning" regime with Fludarabine and Treosulfane (FluTreo) or to non-myeloablative HSCT.
Eligibility
Primary outcome measure(s)
- Cohort 1 and Cohort 2 Medical treatment complications — From baseline to 1 year follow-up
Incidens rate of medical complications (mortality, re-hospitalization, infections, all cause disease relapse, chronic GVHD, return to work)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Rigshospitalet | Copenhagen | Denmark |
More Copenhagen University Hospital, Rigshospitalet trials in Denmark
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04167683 on ClinicalTrials.gov ↗ ← All trials in Denmark